AB-Biotics pospone su plan para cotizar fuera de España
Intel ID : 210824
|
Synopsis
25 JUL 2013
|
|
(content in spanish)
La biotecnológica española AB-Biotics retrasa sus planes para empezar a cotizar en un mercado bursátil extranjero, además del Mercado Alternativo Bursátil (MAB), en el que cotiza desde 2010. En concreto, la firma fundada por Sergi Audivert y Miquel Àngel Bonachera, estaba analizando tres posibilidades: el Nasdaq estadounidense, el AIM británico o el Alternext francés. |
| Intel ID | 210824 | |
| Value | ND | |
| Native Currency | Euro (EUR) | |
|
Financial Data - AB-Biotics
(31 Dec 2021) |
Revenue: - EBITDA: - Net Debt: - People: 35 |
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography |  |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.